Clinical trials: Primary Open Angle Glaucoma
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Glaucoma, Primary Open Angle
Safety and Feasibility of the ELIOS System in POAG Patients
Evaluation of the safety and effectiveness of the ELIOS System procedure to reduce intraocular pressure (IOP) in adult subjects with mild to moderate primary open-angle glaucoma (POAG)
- Trial name
- NCT05999006
- Testing
- ELIOS Procedure
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Elios Vision, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
To evaluate the safety and efficacy of PF-04217329.
- Trial name
- NCT00572455
- Testing
- PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose
- Where
- 23 sites in United States
- Volunteers
- 318 people
- Sponsor
- Pfizer
Glaucoma, Open-Angle, Ocular Hypertension
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
- Trial name
- NCT01489670
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Switzerland
- Volunteers
- 387 people
- Sponsor
- Allergan
Glaucoma
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
- Trial name
- STAR-V (NCT05024695)
- Testing
- MINIject™ Implant
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 975 people
- Sponsor
- iSTAR Medical
Glaucoma, Eye Diseases
A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma
Prospective, unmasked, evaluation of the iStent in patients that have primary open-angle glaucoma (OAG). Stent implantation in one eye will be used for analysis, with medication added at 6 months, as required.
- Conditions
- Glaucoma, Eye Diseases, Glaucoma, Open-Angle
- Trial name
- SY (NCT00911924)
- Testing
- iStent
- Where
- 13 sites in Armenia, Austria and 4 more
- Volunteers
- 112 people
- Sponsor
- Glaukos Corporation
Glaucoma
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
- Trial name
- NCT07168902
- Testing
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Where
- 14 sites in United States
- Volunteers
- 252 people
- Sponsor
- Bausch & Lomb Incorporated
Glaucoma, Glaucoma, Open Angle
AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys XEN 45 Glaucoma Implant in eyes with refractory glaucoma.
- Trial name
- NCT02036541
- Testing
- AqueSys XEN 45 Glaucoma Implant
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- AqueSys, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects
This single-site, dose-escalation study will evaluate safety and tolerability of increasing concentrations of ATS907 in 12 subjects with Primary Open Angle Glaucoma and/or Ocular Hypertension
- Trial name
- NCT01668524
- Testing
- ATS907
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Altheos, Inc.
Glaucoma, Ocular Hypertension
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
The objective of this dose-escalation study is to evaluate the safety, tolerability and efficacy of AMA0076 in reduction of intraocular pressure in subjects with ocular hypertension or primary open-angle glaucoma.
- Conditions
- Glaucoma, Ocular Hypertension, Eye Disease
- Trial name
- NCT01693315
- Testing
- AMA0076
- Where
- 6 sites in United States
- Volunteers
- 82 people
- Sponsor
- Amakem, NV
Primary Open Angle Glaucoma, Healthy Subjects
Efficacy of 24-hour Intraocular Pressure Fluctuation Recording With the SENSIMED Triggerfish Contact Lens Sensor
The objectives of this study are to assess the safety and effectiveness of the SENSIMED Triggerfish® (TF) device in continuous recording of relative fluctuation in intraocular pressure (IOP).
- Trial name
- NCT01390779
- Testing
- SENSIMED Triggerfish
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sensimed AG
Glaucoma, Ocular Hypertension
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
- Trial name
- NCT01123785
- Testing
- INO-8875
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Inotek Pharmaceuticals Corporation
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
This is a randomized, Investigator-masked, multi-center, parallel group, therapeutic equivalence study with clinical endpoint.
- Trial name
- NCT05022004
- Testing
- Brinzolamide ophthalmic suspension, Azopt®
- Where
- 40 sites in India, Russia
- Volunteers
- 599 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular Hypertension
To investigate safety, efficacy, and the dose-response relationship of DE-104 in lowering intraocular pressure in Japanese and Non-Japanese subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00868894
- Testing
- DE-104 medium concentration, DE-104 high concentration, 0.005% latanoprost
- Where
- 6 sites in United States
- Volunteers
- 49 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma
The Effects of an Antioxidant Formulation on Ocular Blood Flow
The objective is to evaluate the effects of an antioxidant formula versus placebo on ocular blood flow in a randomized double-blind, crossover design.
- Trial name
- NCT01930487
- Testing
- dietary supplement with antioxidants
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- ScienceBased Health
Open-angle Glaucoma or Ocular Hypertension
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
- Trial name
- NCT01868126
- Testing
- DE-117 ophthalmic solution, latanoprost ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Santen Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle…
- Trial name
- CONFORTK (NCT03257813)
- Testing
- PRO-122, Krytantek Ofteno®
- Volunteers
- 60 people
- Sponsor
- Laboratorios Sophia S.A de C.V.